tradingkey.logo

Burning Rock Biotech Ltd

BNR
查看詳細走勢圖
34.000USD
+3.340+10.91%
收盤 02/06, 16:00美東報價延遲15分鐘
306.98M總市值
虧損本益比TTM

Burning Rock Biotech Ltd

34.000
+3.340+10.91%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+10.91%

5天

-0.18%

1月

+45.30%

6月

+398.53%

今年開始到現在

+68.73%

1年

+424.69%

查看詳細走勢圖

TradingKey Burning Rock Biotech Ltd股票評分

單位: USD 更新時間: 2026-02-06

操作建議

Burning Rock Biotech Ltd當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在醫療服務供應商行業排名63/75位。機構持股佔比非常高,中期看,股價處於上升通道。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Burning Rock Biotech Ltd評分

相關信息

行業排名
63 / 75
全市場排名
365 / 4521
所屬行業
醫療服務供應商

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

Burning Rock Biotech Ltd亮點

亮點風險
Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
業績增長期
公司處於發展階段,最新年度總收入71.08M美元
估值低估
公司最新PE估值-20.91,處於3年歷史低位
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉31.72K股

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Burning Rock Biotech Ltd新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Burning Rock Biotech Ltd簡介

Burning Rock Biotech Ltd is a Company principally engaged in developing and providing cancer therapy selection tests. The Company operates three businesses, including central laboratory business, in-hospital business and pharma research and development services. Central laboratory business mainly includes the sales of its cancer therapy selection test to individual patient customers. In-hospital business includes the manufacture and sales of reagent kits, as well as the provision of facilitation services for laboratory equipment sold to hospitals. The pharma research and development services include a range of cancer therapy selection test services, analytical validation services and project management services.
公司代碼BNR
公司Burning Rock Biotech Ltd
CEOHan (Yusheng)
網址https://www.brbiotech.com/
KeyAI